DALLAS, Texas - Today’s Trade Alerts include: DUSA Pharmaceuticals Inc. (Nasdaq: DUSA), MiddleBrook Pharmaceuticals Inc. (Nasdaq: MBRK), NovaMed Inc. (Nasdaq: NOVA), Adolor Corp. (Nasdaq: ADLR), Affymetrix Inc. (Nasdaq: AFFX) and Abaxis Inc. (Nasdaq: ABAX).
“DUSA Pharmaceuticals Inc. (DUSA) shares slowly climbed after Friday’s opening bell, inching up nearly 1% to $1.40. DUSA, an integrated dermatology pharmaceutical company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions in the United States and internationally...
“DUSA recently reported Nicomide, a vitamin-mineral product currently prescribed by dermatologists, which DUSA acquired the product through its merger with Sirius Laboratories Inc., will no longer be manufactured and marketed as a prescription product…
“The company's decision came as a proactive action in response to discussions with the U.S. Food and Drug Administration (FDA) since the latter is strengthening its effort to enforce and implement its policy entitled ‘Marketed New Drugs without Approved NDAs or ANDAs.’ The policy seeks to ensure that certain prescription products, like Nicomide, which were historically marketed without approved FDA pre-market applications, comply in a timely manner with current regulations...”
“MiddleBrook Pharmaceuticals Inc. (MBRK) shares tried to recover from yesterday’s loss, climbing 3% to $2.07 Friday morning. MiddleBrook develops and commercializes anti-infective drug products for the treatment of infectious diseases…
“The company recently announced Edward M. Rudnic will step down from his role as president and CEO of the company, complying with the terms of Equity Group Investments LLC's $100 million investment in the company. Proceeds from the investment will fund the launch of its once-daily Moxatag amoxicillin antibiotic, and help continue pipeline development…
“Pursuant to the agreement, MiddleBrook is selling 30.3 million common shares at $3.30 each to Equity Group and a five-year warrant to buy 12.1 million shares at an exercise price of $3.90 each. MiddleBrook also agreed to repurchase its Keflex assets previously sold to Deerfield Management affiliates in November 2007 for about $11 million…”
Investors can view all of the TraderNotes and investment articles for free by visiting:
http://www.beaconequity.com/m
Join the fastest growing investor community at:
http://www.stockhideout.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquity.com/m
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com
Beacon Equity Research Disclosure
The analysts contributing to this report do not hold any shares of DUSA Pharmaceuticals Inc. (Nasdaq: DUSA). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research (“Beacon”) certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
